Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) EBT Margin (2016 - 2023)

Spyre Therapeutics' EBT Margin history spans 7 years, with the latest figure at 31551.45% for Q2 2023.

  • For Q2 2023, EBT Margin fell 2798121.0% year-over-year to 31551.45%; the TTM value through Mar 2024 reached 52933.58%, down 4623838.0%, while the annual FY2023 figure was 38241.08%, 3463649.0% down from the prior year.
  • EBT Margin reached 31551.45% in Q2 2023 per SYRE's latest filing, down from 9322.22% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 56.15% in Q2 2021 to a low of 31551.45% in Q2 2023.
  • Average EBT Margin over 3 years is 7644.89%, with a median of 3570.24% recorded in 2022.
  • Peak YoY movement for EBT Margin: tumbled -351409bps in 2022, then plummeted -2798121bps in 2023.
  • A 3-year view of EBT Margin shows it stood at 560.46% in 2021, then crashed by -1895bps to 11180.95% in 2022, then plummeted by -182bps to 31551.45% in 2023.
  • Per Business Quant, the three most recent readings for SYRE's EBT Margin are 31551.45% (Q2 2023), 9322.22% (Q1 2023), and 11180.95% (Q4 2022).